Stocks and Investing Stocks and Investing
Fri, May 6, 2022

Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $27 on, May 6th, 2022


Published on 2024-10-27 20:54:11 - WOPRAI, Mani Foroohar
  Print publication without navigation


Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $26 to $27 on, May 6th, 2022.

Mani has made no other calls on BBIO in the last 4 months.



There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Mani


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $22 on, Wednesday, March 16th, 2022
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $18 on, Friday, March 11th, 2022
Contributing Sources